DDInter909 DDInter704
Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and typically occurred in the first four weeks of therapy".. The discovery of imatinib also established a new group of therapy called "targeted therapy", since treatment can be tailored specifically to the unique cancer genetics of each patient. Imatinib was approved on February 1st,2001 by the FDA and November 7th, 2001 by the EMA; however, its European approval has been withdrawn in October 2023.[A263036,L49746,L49751]
Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
Imatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Imatinib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Everolimus
Imatinib {u} (Compound) binds {v} (Gene) KIT
KIT {u} (Gene) is upregulated by {v} (Compound) Everolimus
Imatinib {u} (Compound) upregulates {v} (Gene) TMEM110
TMEM110 {u} (Gene) is upregulated by {v} (Compound) Everolimus
Imatinib {u} (Compound) downregulates {v} (Gene) HAT1
HAT1 {u} (Gene) is downregulated by {v} (Compound) Everolimus
Imatinib {u} (Compound) causes {v} (Side Effect) Pericardial effusion
Pericardial effusion {u} (Side Effect) is caused by {v} (Compound) Everolimus
Imatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Pimecrolimus
Pimecrolimus {u} (Compound) resembles {v} (Compound) Everolimus
Imatinib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Pimecrolimus
Pimecrolimus {u} (Compound) resembles {v} (Compound) Everolimus
Imatinib {u} (Compound) binds {v} (Gene) KIT
KIT {u} (Gene) is associated with {v} (Disease) kidney cancer
kidney cancer {u} (Disease) is treated by {v} (Compound) Everolimus
Imatinib {u} (Compound) upregulates {v} (Gene) TMEM110
TMEM110 {u} (Gene) is regulated by {v} (Gene) NOTCH1
NOTCH1 {u} (Gene) is upregulated by {v} (Compound) Everolimus
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound)
Imatinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Everolimus (Compound)
Imatinib (Compound) binds KIT (Gene) and KIT (Gene) is upregulated by Everolimus (Compound)
Imatinib (Compound) upregulates TMEM110 (Gene) and TMEM110 (Gene) is upregulated by Everolimus (Compound)
Imatinib (Compound) downregulates HAT1 (Gene) and HAT1 (Gene) is downregulated by Everolimus (Compound)
Imatinib (Compound) causes Pericardial effusion (Side Effect) and Pericardial effusion (Side Effect) is caused by Everolimus (Compound)
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Pimecrolimus (Compound) and Pimecrolimus (Compound) resembles Everolimus (Compound)
Imatinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Pimecrolimus (Compound) and Pimecrolimus (Compound) resembles Everolimus (Compound)
Imatinib (Compound) binds KIT (Gene) and KIT (Gene) is associated with kidney cancer (Disease) and kidney cancer (Disease) is treated by Everolimus (Compound)
Imatinib (Compound) upregulates TMEM110 (Gene) and TMEM110 (Gene) is regulated by NOTCH1 (Gene) and NOTCH1 (Gene) is upregulated by Everolimus (Compound)